Question explored with the scientific record
Conversation so far
- 1 Symptoms tuberculosis
- 2 Treatment equivaruus talus
Answered on this page ↓
Treatment equivaruus talus
TB treatment is long, multi-drug, and hard on the liver, and the drug-resistant forms are where it gets genuinely dangerous.
For active, drug-sensitive TB, the standard is a multi-drug cocktail. The retrieved evidence shows the four core drugs (rifampin, isoniazid, pyrazinamide, ethambutol) modeled together, with rifampin and isoniazid doing most of the killing [1]. A single case report describes a man whose peritoneal TB resolved after six months on isoniazid, rifampin, ethambutol, and pyrazinamide [3].
The liver is the real cost. In a pooled analysis of over 6,000 people treated for latent TB, rifampin caused fewer drug-related side effects than isoniazid (about 2 in 100 vs 4 in 100) and far less serious liver injury (11 vs 65 cases) [2]. But co-infection changes the math: hepatitis C roughly triples the risk of drug-induced liver injury during TB treatment [4], and hepatitis B raises it sharply too [8]. A South African cohort put overall liver-injury incidence at about 2 in 100 treated patients [5].
| Regimen / group | Liver injury or side effects |
|---|---|
| Rifampin (latent TB) | 11 serious liver cases of 3,280 [2] |
| Isoniazid (latent TB) | 65 serious liver cases of 3,205 [2] |
| TB + hepatitis C | ~3.5x higher liver injury risk [4] |
| TB + hepatitis B | markedly higher risk [8] |
Drug-resistant TB is a different problem. In Ethiopian MDR-TB data, pooled treatment success was only about 59 in 100 [7]. In migrants treated in Italy, success reached about 82 in 100 [6]. Bedaquiline for MDR-TB produced favorable outcomes in about 80 in 100, but with heart-rhythm (QT) prolongation in 13 of 45 patients [9].
This retrieval does not include the current WHO first-line regimen durations or the newest short-course resistant-TB regimens, so I cannot give you exact schedules from these records.
My call: for drug-sensitive active TB, the four-drug regimen is well justified and the liver risk is manageable with monitoring, especially if you are tested for hepatitis B and C first [4][8]. For resistant TB, outcomes are meaningfully worse and the drugs carry real cardiac and liver risk [7][9]. Confidence: moderate.
Sources used 9
-
Mathematical model and tool to explore shorter multi-drug therapy options for active pulmonary tuberculosis
An integrated population PK/PD systems pharmacology model (TBsim) combines host immune dynamics, granuloma biology, bacterial resistance, and drug penetration to explore shorter multi-drug tuberculosis therapies, validate against clinical trends, and provide an open-source web t…
DOI: 10.1371/journal.pcbi.1008107 -
Safety and Efficacy of Rifampin or Isoniazid Among People With Mycobacterium tuberculosis Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized Trials
Four months of rifampin for latent TB infection demonstrated comparable prevention of active TB to nine months of isoniazid, with higher treatment completion and fewer drug-related adverse events across adults—including those with HIV or other health conditions—highlighting rifa…
DOI: 10.1093/cid/ciaa1169 -
Peritoneal Tuberculosis Mimicking Peritoneal Carcinomatosis
A 67-year-old man with ascites that appeared as peritoneal carcinomatosis was ultimately diagnosed with peritoneal tuberculosis by biopsy, AFB, PCR/culture; ascites and carcinomatosis resolved after 6 months of anti-tuberculosis treatment.
DOI: 10.1155/2014/436568 -
Risk of drug-induced liver injury in chronic hepatitis C and tuberculosis co– infection: a systematic review and meta– analysis
This meta-analysis of 13 studies involving 3,174 tuberculosis patients shows that co-infection with chronic hepatitis C markedly increases the risk and severity of anti-tuberculosis drug-induced liver injury (ATDILI), supporting routine HCV screening and tailored treatment to mi…
DOI: 10.1186/s12879-025-12005-y -
Incidence and associated risk factors of anti-tuberculosis drug induced liver injury among TB patients
An ambispective multicohort case-control study in South Africa quantified the incidence of anti-tuberculosis drug-induced liver injury (ATDILI) at 2.1% among 610 TB patients and identified female sex, HIV infection, and alcohol use as independent risk factors, with higher ALT el…
DOI: 10.1186/s12879-025-11796-4 -
Epidemiology and treatment outcome of MDR and pre-XDR TB in international migrants at two reference centers in the North of Italy: a cross-sectional study coordinated by Stop TB Italia Onlus
A retrospective cross-sectional study evaluating the epidemiology and treatment outcomes of MDR- and pre-XDR-TB in international migrants at two northern Italian TB reference centers (2000–2015), reporting an overall treatment success of 81.9% and detailing demographics, disease…
DOI: 10.1016/j.puhe.2019.10.022 -
Current treatment of multidrug resistant tuberculosis in Ethiopia: an aggregated and individual patients’ data analysis for outcome and effectiveness of the current regimens
A systematic review and meta-analysis of MDR-TB treatment outcomes in Ethiopia using aggregated and individual patient data from six observational studies (n=1993), finding a pooled treatment success of 59.2% with notable proportions not evaluated and a need to validate and upda…
DOI: 10.1186/s12879-018-3401-5 -
Impacts of hepatitis B and hepatitis C co-infection with tuberculosis, a prospective cohort study
A large prospective cohort study in West Gojam, Ethiopia, of 3,537 TB patients on DOTS assessed the prevalence and determinants of hepatitis B and C co-infection, their impact on TB treatment outcomes and hepatotoxicity, and patient survival until drug-induced hepatitis, reveali…
DOI: 10.1186/s12985-020-01385-z -
Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis
An observational, multicenter French cohort study assessing long-term outcomes and safety of prolonged bedaquiline treatment (>24 weeks) in multidrug-resistant TB (MDR-TB), reporting around 80% favourable outcomes with substantial adverse events and QT prolongation, and finding …
DOI: 10.1183/13993003.01799-2016